Cover Image
市場調查報告書

緩釋性注射劑市場

Sustained Release Injectables

出版商 Greystone Research Associates 商品編碼 172258
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
緩釋性注射劑市場 Sustained Release Injectables
出版日期: 2016年01月01日 內容資訊: 英文
簡介

注射劑可延長投藥的作用期間,同時降低投藥頻率,能克服醫療的各種課題。如果投藥的回數能減少,可提高患者的安全性, 抑制注射部位的併發症發生,在改善對通訊協定的適合性。緩釋性注射劑可抑制藥物副作用。隨著高齡化慢性疾病的發病率和盛行率的上升,對緩釋性注射劑的關注高漲。

本報告提供緩釋性注射劑經濟性方面和技術,有效的疾病,可商業性的詳細分析,市場上各種要素和商業化策略,以及主要企業簡介,為您概述為以下內容。

摘要整理

緩釋性 - 首發製劑技術

  • 生物分解性聚合物
  • 首發緩釋性製劑技術
  • 物理的流程控製法

緩釋性注射劑 - 開發要素

  • 製劑要素
    • 穩定性
  • 給藥要素

緩釋性注射劑 - 產品分析 & 市場部門預測

  • 成癮
    • naltrexone
  • 糖尿病
    • Exenatide
  • 感染疾病
    • 干擾素
  • 荷爾蒙缺乏症
    • 雌激素
    • 生長激素
    • 睪固酮
  • 代謝疾病
    • 肢端肥大症
  • 神經學
    • Aripiraole
    • Fluphenazine
    • Haloperidol
    • Paliperidone
    • Olanzapine
    • Risperidone
  • 腫瘤學
    • 白血病
    • 淋巴瘤
    • 前列腺
  • 疼痛管理
    • Bupivacaine
  • 生殖醫療
    • Medroxyprogesterone

正在開發的緩釋性注射劑

緩釋性注射劑:企業簡介

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: SRJ733K

The ability to formulate injectable drugs to increase the duration of efficacy for a given dose and simultaneously reduce the dosing frequency addresses several important health care issues. Less frequent dosing is believed to improve patient safety, reduce the incidence of injection site complications and improve compliance with drug protocols. Sustained release formulations mitigate the bolus effect at the time of injection, and thus have a salutary influence on drug side effects. All of these advantages, along with the need for fewer patient caregiver visits (for practitioner-administered drugs) have a positive, downward impact on overall healthcare costs. Currently approved sustained release injectables rely on a spectrum of branded formulation technologies to modulate the drug's release profile post-injection. Typically off-patent or generic drugs, they include drug therapies for almost a dozen major therapeutic segments, including neurological conditions, metabolic diseases, oncology, pain management and reproductive health. As the incidence and prevalence of chronic illnesses increases with the aging population, the attraction and interest in sustained release injectables to 2022 will increase.

Sustained Release Injectables - What You Will Learn

  • What are the marketed sustained release injectable drug products, what sustained release formulation technologies are used, and who markets them?
  • What are the major factors driving sustained release injectable drug demand?
  • What sustained release injectable drug candidates are in late-stage clinical development and what is their potential impact?
  • How important are drug developer-formulation technologist relationships in the sustained release market segment, and what are the key alliances in the industry?
  • What are the essential formulation factors, delivery device selection issues, related technology factors and market development issues for sustained release injectable drug products?
  • In what therapeutic market segments do sustained release injectables compete? What is their market share today? What will it be in 2022? What is their expected growth rate?
  • What are the significant economic, technology, and regulatory factors affecting the market for sustained release injectables?

Table of Contents

Sustained Release Injectables - Summary of Contents

Executive Summary

  • Injectable Drug Market Dynamics
  • The Trend toward Self-Administration
  • Injectable Drug Formulation Technology
  • Innovation in Injectable Device Designs
  • Therapeutic Demand Drivers
  • Market Factors
  • Competitive Landscape
  • Risk Factors

Sustained Release - Branded Formulation Technologies

  • Biodegradable Polymers
  • Branded SR Formulation Technologies
  • Physical Process Control Methods

Sustained Release Injectables - Development Factors

  • Formulation Factors
    • Stability
      • Lyophilization
      • Packaging
  • Administration Factors

SR Injectables - Product Analysis & Market Sector Forecasts

  • Addiction
    • Naltrexone
  • Diabetes
    • Exenatide
  • Infectious Disease
    • Interferon
  • Hormone Deficiency
    • Estradiol
    • Somatropin
    • Testosterone
  • Metabolic Diseases
    • Acromegaly
      • Lanreotide
      • Octreotide
  • Neurology
    • Aripiraole
    • Fluphenazine
    • Haloperidol
    • Paliperidone
    • Olanzapine
    • Risperidone
  • Oncology
    • Leukemia
      • Vincristine
    • Lymphoma
      • Cytarabine
    • Prostate
      • Goserelin
      • Leuprolide
      • Triptorelin
  • Pain Management
    • Bupivacaine
  • Reproductive Health
    • Medtroxyprogesterone

Development-stage SR Injectables

Sustained Release Injectables - Company Profiles

Back to Top